News about "Biogen"

Biogen Announces Topline Phase 2 Results for Diranersen in Early Alzheimer's Disease

Ionis partner Biogen announces topline phase 2 CELIA trial results for diranersen (BIIB080), showing reduced tau pathology and cognitive benefits in patients with early Alzheimer's Disease (AD).

Biogen | 15/05/2026 | By News Bureau

LEQEMBI IQLIK Subcutaneous Dose Gets US FDA Priority Review for Early Alzheimer's Disease

LEQEMBI IQLIK subcutaneous dose review by US Food and Drug Administration (FDA) extended after major sBLA amendment for early Alzheimer’s disease, with no approvability concerns raised.

Biogen | 11/05/2026 | By News Bureau

Biogen to Acquire Apellis, Expands Immunology and Rare Disease Portfolio

Biogen to acquire Apellis for USD 5.6 billion, adding EMPAVELI and SYFOVRE to expand its immunology, rare disease and nephrology portfolio and drive long-term growth.

Biogen | 01/04/2026 | By News Bureau

Alteogen and Biogen Sign Deal for Hybrozyme-Based Subcutaneous Biologics

Alteogen signs a licensing deal with Biogen to develop and commercialise Hybrozyme-based subcutaneous biologics, granting rights for two products using the ALT-B4 platform.

Biogen | 26/03/2026 | By News Bureau |  189

Samsung Bioepis Launches BYOOVIZ Biosimilar in Europe

Samsung Bioepis has completed the transfer of BYOOVIZ commercial rights from Biogen, making it the company’s fourth biosimilar directly marketed in Europe, with a pre-filled syringe launch planned for Q2 2026.

Biogen | 03/01/2026 | By News Bureau |  154

Biogen Partners with Dayra Therapeutics to Develop Oral Macrocyclic Peptide Treatments for Immunological Diseases

Biogen Inc. has entered into a research collaboration with Dayra Therapeutics to discover and develop oral macrocyclic peptides targeting high-priority immunological conditions.

Biogen | 26/11/2025 | By Darshana |  150

Biogen licences Vanqua Bio's immune-disorder drug in deal worth up to USD 1.06 billion

Biogen has entered into an agreement with Vanqua Bio to acquire global rights to an experimental oral therapy for immune-related disorders, in a deal valued at up to USD 1.06 billion.

Biogen | 27/10/2025 | By Darshana |  240

US FDA Declines Approval for Biogen's Higher-Dose Spinraza in SMA

The decision was relayed via a ‘complete response letter’ to Biogen, which clarified there were no issues with the clinical data behind the new high-dose regimen. Biogen says it will resubmit the application promptly, drawing on information that is already at hand.

Biogen | 24/09/2025 | By Darshana |  167

Samsung Bioepis Partners with Harrow for US Commercialisation of Ophthalmology Biosimilars

Following the transition of commercial rights from Biogen back to Samsung Bioepis, Harrow will assume full responsibility for the commercialisation of both BYOOVIZ and OPUVIZ biosimilars in the US.

Biogen | 18/07/2025 | By Dineshwori |  318

Biogen and Stoke Therapeutics to Develop and Commercialize Zorevunersen

Zorevunersen is an investigational antisense oligonucleotide (ASO) that targets the SCN1A gene, the underlying cause of most cases of Dravet syndrome.

Biogen | 20/02/2025 | By Aishwarya |  374